Kemin Expands Vaccine Research for Livestock Health
Kemin Industries is expanding its role in livestock disease prevention through the acquisition of Hennessy Research Associates, LLC. The Kansas-based firm specializes in vaccine research and development. With this move, Kemin adds more than 50 experienced scientists and strengthens its biologics division.
Expertise in Vaccine Development
For more than 20 years, Hennessy Research Associates has focused on vaccines for infectious animal diseases. The team has expertise in biological manufacturing, in vitro test development, host-animal challenge models, and USDA-approved diagnostic testing. By joining Kemin, these capabilities will be part of a global platform that supports livestock health and vaccine innovation.
A Legacy of Research Leadership
The company was founded in 2001 by Dr. Kristina J. Hennessy, a Board-Certified veterinary immunologist with decades of experience. She has developed patented solutions for animal health and guided her team in creating practical, science-based tools for disease prevention. With this acquisition, Dr. Hennessy and her researchers will continue their work under the Kemin umbrella.
Building Global Animal Health Capacity
The acquisition also broadens the scope of Kemin Biologics. The unit will now offer expanded services in contract research, vaccine development, and full-scale manufacturing. This strengthens Kemin’s presence in the U.S. “animal health corridor” and increases its ability to provide safe, effective, and affordable solutions for livestock producers.
Kemin President and CEO Dr. Chris Nelson said the acquisition marks an important step forward: “This allows us to strengthen our position in the U.S. and global animal health markets with additional expertise and science-backed research that is critical to ensure the health and welfare of animals worldwide.”
